INFLUENCE OF CYP2D6 POLYMORPHISMS ON CLINICAL OUTCOMES AND QUALITY OF LIFE IN RISPERIDONE-TREATED PATIENTS WITH SCHIZOPHRENIA
Keywords:
Schizophrenia, Quality of life (QOL), RisperidoneAbstract
Introduction: Schizophrenia is a chronic mental disorder that significantly affects patients’ quality of life (QoL), despite antipsychotic treatment. Variability in therapeutic response and frequent adverse effects pose major challenges, making QoL a crucial treatment outcome.
Aim: To assess the impact of CYP2D6 genetic polymorphisms, psychopathology, and adverse drug reactions on subjective QoL in patients with schizophrenia treated with risperidone.
Material and methods: A prospective observational study was conducted at the University Clinic for Psychiatry, Ss. Cyril and Methodius University in Skopje. Ninety-one adult patients (20–63 years; 42 males, 49 females) with ICD-10 F20–F29 psychotic disorders treated with risperidone (1–6 mg/day) were evaluated on admission and discharge using SQLS, PANSS, and BPRS scales. Patients were classified by CYP2D6 metabolic phenotype. Data were analyzed using SPSS v23.0; p < 0.05 was considered significant.
Results: CYP2D6 phenotype significantly influenced QoL, with poor metabolizers showing lower scores than moderate and extensive metabolizers (p=0.00003). Psychopathology severity strongly correlated with reduced QoL on discharge. Specific adverse effects, including anxiety (p=0.026), dizziness (p=0.00007), vertigo (p=0.004), suboptimal effect (p=0.00003), and rigor (p = 0.022), were associated with QoL impairment.
Conclusion: CYP2D6 pharmacogenomic profiling can guide personalized risperidone therapy, reducing adverse effects and improving QoL. Optimal control of psychopathology and proactive management of side effects are essential for enhancing patient outcomes.
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Primers 2015; 1: 15067. doi:10.1038/nrdp.2015.67.
World Health Organization. Schizophrenia [Internet]. Geneva: WHO; 2022 [cited 2025 Sep 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia
Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016; 12: 357-373. doi:10.2147/NDT.S96649.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines. Am J Psychiatry 2017; 174(3): 216-229. doi: 10.1176/appi.ajp.2017.17010003.
Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013; 13:50. doi:10.1186/1471-244X-13-50.
Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective cohort study. Lancet Psychiatry 2019; 6(5): 418-426. doi: 10.1016/S2215-0366(19)30088-4.
Islam F, Men X, Yoshida K, Zai C, Müller DJ. Pharmacogenetics-guided advances in antipsychotic treatment. Clin Pharmacol Ther 2021; 110(3): 582-588. doi: 10.1002/cpt.2339.
Filipce A, Naumovska Z, Kapedanovska-Nestorovska A, Sterjev Z, Brezovska K, Tonic-Ribarska J, et al. Evaluation of correlation between pharmacogenetic profiles of risperidone-treated patients and plasma/urine concentrations of risperidone and 9-OH-risperidone. Prilozi 2018; 39(2-3): 97-106. doi:10.2478/prilozi-2018-0047.
Kapedanovska-Nestorovska A, Jakovski K, Naumovska Z, Hiljadnikova-Bajro M, Sterjev Z, Eftimov A, et al. Distribution of the most common genetic variants associated with variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet 2015; 17(2): 5-14. doi:10.2478/bjmg-2014-0069.
Ribarski O, Mladenovska E, Stamatovska K, Kirijas M. Genetic polymorphisms of CYP2C9 gene among voluntary donors from the Macedonian Bone Marrow Donor Registry and its implications on therapeutic dosage of non-steroidal anti-inflammatory drugs. Acad Med J 2022; 2(2): 40-46. doi:10.53582/AMJ2222040r.
de León J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66(1): 15-27. doi:10.4088/JCP.v66n0103.
Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J, et al. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013; 23(11): 627-630. doi: 10.1097/FPC.0b013e3283649bcb.
Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010; 66(11): 1109-1117. doi: 10.1007/s00228-010-0867-y.
Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet 2015; 54(12): 1259-1272. doi: 10.1007/s40262-015-0286-9.
Hendset M, Molden E, Knape M, Hermann M. Serum concentrations of risperidone and aripiprazole in CYP2D6 intermediate metabolizer subgroups. Ther Drug Monit 2014; 36(1): 80-85. doi: 10.1097/FTD.0b013e3182a76d3a.
Naumovska Z, Kapedanovska-Nestorovska A, Jakovski K, Sterjev Z, Eftimov A, Dimovski A. Distribution of the most common genetic variants associated with variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet 2015; 17(2): 5-14. doi: 10.2478/bjmg-2014-0069.
Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, et al. Impact of CYP2D6 and DRD2 markers on prolactin response in risperidone-treated children/adolescents with autism. J Clin Psychopharmacol 2016; 36(2): 141-146. doi: 10.1097/JCP.0000000000000482.
Hongkaew Y, Ngamsamut N, Vanwong N, Puangpetch A, Chamnanphon M, Sukasem C. Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. Neuropsychiatr Dis Treat 2015; 11: 191-196. doi: 10.2147/NDT.S75007.
Ngamsamut N, Hongkaew Y, Vanwong N, Srisawasdi P, Puangpetch A, Chamkrachangpada B, et al. 9-Hydroxyrisperidone-induced hyperprolactinaemia in Thai children/adolescents with autism. Basic Clin Pharmacol Toxicol 2016; 119(3): 267-272. doi: 10.1111/bcpt.12580.
Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, et al. DRD2 variants and risperidone-induced hyperprolactinemia in children/adolescents. Pharmacogenet Genomics 2009; 19(5): 373-382. doi: 10.1097/FPC.0b013e32832a3c97.
Cartwright AL, Wilby KJ, Corrigan S, Ensom MH. Pharmacogenetics of risperidone: systematic review of CYP2D6 effects. Ann Pharmacother 2013; 47(3): 350-360. doi: 10.1345/aph.1R567.
Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011; 11(1): 1-14. doi:10.1038/tpj.2010.78.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-276. doi:10.1093/schbul/13.2.261.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10(3): 799-812. doi: 10.2466/pr0.1962.10.3.799.
Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000; 177(1): 42-46. doi: 10.1192/bjp.177.1.42.
Mitrevska T. Correlation between quality of life and demographic characteristics of patients with vitiligo in North Macedonia. Acad Med J 2023; 3(3): 41-48. doi: 10.53582/AMJ2333041tm.
Vasiliu O. Pharmacogenetics of new-generation antipsychotics: a review. Front Psychiatry 2023; 14: 1124796. doi: 10.3389/fpsyt.2023.1124796.
Lock SK, Kappel DB, Owen MJ, Walters JTR, O'Donovan MC, Pardiñas AF, et al. Antipsychotic and pharmacogenomic effects on cross-phenotype severity in psychiatric disorders. EBioMedicine 2025; 104: 105245. doi: 10.1016/j.ebiom.2025.105245.
Carrascosa-Arteaga A, Nalda-Molina R, Más-Serrano P, Ramon-Lopez A. Population pharmacokinetics of risperidone and paliperidone in schizophrenia: a systematic review. Pharmaceuticals (Basel) 2025; 18(5): 698. doi: 10.3390/ph18050698.
Sharew NT, Clark SR, Schubert KO, Amare AT. Pharmacogenomic scores for psychiatric treatment: a systematic review. Front Genet 2024; 15: 1336548. doi: 10.3389/fgene. 2024.1336548.
Du H, Ma J, Zhou W, Li M, Huai C, Shen L, et al. Methylome-wide association study of differential responses to risperidone in schizophrenia. Front Pharmacol 2022; 13: 1078464. doi: 10.3389/fphar.2022.1078464.
Zhao Y, et al. Differential responses to risperidone treatment in schizophrenia: a genome-wide association and exome sequencing study. Transl Psychiatry 2022; 12: 489. doi: 10.1038/s41398-022-01942-w.
Yoshida K, Müller DJ. Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. Mol Neuropsychiatry 2020; 5(Suppl 1): 1-26. doi: 10.1159/000492332.
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9(5): 442-473. doi: 10.1038/sj.mp.4001494.
Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, Llerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98(2): 127-34. doi:10.1002/cpt.147.
Priebe S, McCabe R, Junghan U, Kallert T, Ruggeri M, Slade M, et al. Association between symptoms and quality of life in patients with schizophrenia: a pooled analysis of changes over time. Schizophr Res 2011; 133(1-3): 17-21. doi: 10.1016/j.schres.2011.09.021.
Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 2017; 11: 449-468. doi: 10.2147/PPA.S124658.
Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013; 64: 393-406. doi: 10.1146/annurev-med-050911-161504.
Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21(11): 911-936. doi: 10.2165/00023210-200721110-00004.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ana Filipce, Zorica Naumovska, Elizabet Miceva Velickovska, Aleksandar Risteski, Biljana Simonovska, Zoja Babinkostova
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under CC BY 4.0 
